Data as of .
ARKG vs GNOM: which is really different?
ARKG and GNOM hold 42% of their weight in the same names, and ARKG returned more over the year.
ETFIQ Off-Index Score: ARKG scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
42% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, ARKG and GNOM hold 42% of their money in the same securities at the same weight.
| Holding | ARKG | GNOM |
|---|---|---|
| TWIST BIOSCIENCE CORP | 9.63% | 7.40% |
| 10X GENOMICS INC-CLASS A | 9.39% | 6.53% |
| GUARDANT HEALTH INC | 4.87% | 5.78% |
| NATERA INC | 4.25% | 5.13% |
| ILLUMINA INC | 4.13% | 5.30% |
| CRISPR THERAPEUTICS AG | 5.63% | 2.89% |
| GENEDX HOLDINGS CORP | 2.43% | 1.96% |
| CAREDX INC | 3.78% | 1.85% |
| ELI LILLY & CO | 3.51% | 1.79% |
| VERACYTE INC | 1.76% | 2.33% |
| BEAM THERAPEUTICS INC | 2.93% | 1.75% |
| INTELLIA THERAPEUTICS INC | 1.49% | 1.03% |
| Only in ARKG | Only in GNOM |
|---|---|
| TEMPUS AI INC-CL A 8.92% | MODERNA INC 7.99% |
| ABSCI CORP 4.76% | GENSCRIPT BIOTECH CORP 4.29% |
| COMPASS PATHWAYS PLC 3.25% | BIO-TECHNE CORP 3.56% |
| SCHRODINGER INC 3.04% | BIOMARIN PHARMACEUTICAL INC 3.41% |
| RECURSION PHARMACEUTICALS-A 2.50% | VERTEX PHARMACEUTICALS INC 3.35% |
| ADAPTIVE BIOTECHNOLOGIES 2.43% | QIAGEN N.V. 3.13% |
| ARCTURUS THERAPEUTICS HOLDIN 2.11% | CARIS LIFE SCIENCES INC 2.72% |
| NURIX THERAPEUTICS INC 2.05% | ARROWHEAD PHARMACEUTICALS IN 2.59% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Sep 18, 2026 and Sep 21, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| ARKG | GNOM | ARKG | GNOM | ARKG | GNOM | |
| 3 months | +40.1% | +27.6% | +37.9 pts | +25.4 pts | +42.6 pts | +30.1 pts |
| 6 months | +98.2% | +56.4% | +80.2 pts | +38.4 pts | +74.0 pts | +32.2 pts |
| 1 year | +87.1% | +77.5% | +70.6 pts | +60.9 pts | +65.4 pts | +55.7 pts |
| 3 years | +74.8% | +59.3% | −3.6 pts | −19.1 pts | −23.4 pts | −38.9 pts |
| Since launch | +174.6% | +9.8% | −186.8 pts | −185.2 pts | −504.0 pts | −297.4 pts |
| ARKG ARK Genomic Revolution ETF Holds 33 stocks in genomics and gene editing, 4% of its weight in S&P 500 companies | GNOM Global X Genomics & Biotechnology ETF Holds 52 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | ARK | Global X |
| Theme | Genomics and gene editing | Genomics and gene editing |
| In the S&P 500 | 3.5% | 20.9% |
| Active share vs the S&P 500 | 98.5% | 97.6% |
| In the Nasdaq-100 | 0.0% | 5.0% |
| Holdings | 33 | 52 |
| Top ten, share of the fund | 60.4% | 52.7% |
| Expense ratio | 0.75% | 0.50% |
| Fee for the differing part | 0.76% | 0.51% |
| Total return, 1 year | +87.1% | +77.5% |
| vs the S&P 500 | +70.6 pts | +60.9 pts |
| vs the Nasdaq-100 | +65.4 pts | +55.7 pts |
| Below its high | −53.8% | −39.6% |
| Net assets | $2.2bn | $100m |
ARKG in plain words
By weight, 4% of ARKG's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 60% of the fund across 33 positions, as published by its issuer for Sep 21, 2026. Over the year to Sep 18, 2026 the fund returned +87.1% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 70.6 pts. It sits 53.8% below its all-time high of Jan 20, 2021.
GNOM in plain words
By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 53% of the fund across 52 positions, as published by its issuer for Sep 18, 2026. Over the year to Sep 18, 2026 the fund returned +77.5% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 60.9 pts. It sits 39.6% below its all-time high of Feb 8, 2021.
Questions people ask
- Do ARKG and GNOM hold the same stocks?
- By their latest filings, 42% of their books are the same securities at the same weight, which is a meaningful overlap. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, ARKG or GNOM?
- ARKG has 4% of its weight in S&P 500 names and GNOM has 21%, so ARKG differs more from the index.
- Which is cheaper, ARKG or GNOM?
- ARKG charges 0.75% a year and GNOM charges 0.50%, so GNOM is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, ARKG against GNOM, data as of Sep 18, 2026. https://etfiq.com/compare/themes/arkg-vs-gnom Free to use with attribution; the underlying files are at Open data.